Los Angeles now has the first clinic in Southern California where anyone can benefit from QT ImagingTM breast scan technology. This breakthrough innovation offers no radiation, non-compression 3D images of the breast to complement traditional mammography and provide added crucial visualization and data — including ductal networks. The first-in-class imaging center, a collaboration between the Dr. Susan Love Foundation for Breast Cancer Research and QTimaging is now open at 145 Robertson Blvd. in Beverly Hills. Appointments are necessary, and the procedure retails for $399 and includes an image reading by a qualified healthcare professional.
“The awareness that more than half of women have dense breast tissue prompted us to seek funding for this tool,” says Christopher Clinton Conway, CEO of the Dr. Susan Love Foundation. “Susan was an instrumental thought partner with QTimaging Founder and CEO Dr. John Klock, and this FDA-cleared innovation is their nextgen contribution to unlocking breast cancer diagnostics and early detection.”
The QTscan option is a true healthcare game changer, offering clinicians never-before-seen 3D images of patients’ breasts to better detect and diagnose breast cancer. The clearest picture is the greatest asset for any patient. Emphasis on diagnostics is foundational to breast cancer treatment.
The debut of this first-in-class breast clinic is the realization of an early partnership between the Dr. Susan Love Foundation, NASA, and QTimaging.
The collaboration and partnership between the Dr. Susan Love Foundation, NASA, and QTimaging has brought forth the reality of a next-generation imaging and detection space, proudly housed in Beverly Hills California — the QTimaging Breast Center.
“Angelenos will be among the first to benefit from this imaging revolution,” says Conway. “But the goal is to include this imaging option as a standard of care globally. We will be collecting data on diagnosis and outcomes to support the efficacy of the QT images so all may benefit.”
Now that the imaging center is open to the public, QTimaging continues to push boundaries developing next phase AI-enhanced diagnostic tools. As AI-based algorithms fuel an acceleration of breakthroughs in medicine, QT plans to unveil AI tools with the QTviewer® which may enable feature analysis with the capability of categorizing findings as either benign or malignant, with the goal of dramatically reducing false positives and unnecessary biopsies. This feature is pending FDA clearance.
The Dr. Susan Love Foundation is also at the forefront of momentum in demonstrating that low-resource communities and countries can also provide women with state-of-the-art diagnostic imaging. Earlier this year, an NIH-funded study launched by Dr. Love concluded with evidence showing how even minimally trained healthcare workers using handheld devices powered by AI can detect masses. The groundbreaking results were published in the Journal of Radiology in May.
The Foundation also leads the efforts to map the breast ducts. The thought is that a clear and detailed mapping of the breast ducts will allow us to really focus in, to eliminate cancer where it starts. The Foundation believes that this mapping is crucial to early detection, and ultimately to treatment.
Later this fall, the 7th edition of The Breast Book by Dr. Susan Love will be published by Hachette, updated with the latest information including new drugs, vaccines, and hormonal treatments, the latest in cellular-level science and genetics, and alternative approaches and prevention. The New York Times calls Dr. Love’s book “the bible” for people with breast cancer.
On July 2, Dr. Susan Love passed away after a recurrence of leukemia. Her global impact was celebrated in stories about her life and work in The New York Times, The Washington Post, The Boston Globe, and the Los Angeles Times. She loved her home in Los Angeles and valued the partnerships with scientists and healthcare professionals at the city’s great institutions including UCLA and JPL. Her vision will continue to guide the breast cancer research, advocacy, and breakthroughs she pioneered.